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REVIEW
Diagnostic aids for detection of oral precancerous
conditions
Diana V Messadi
Oral cancer has a tendency to be detected at late stage which is detrimental to the patients because of its high mortality and morbidity
rates. Early detection of oral cancer is therefore important to reduce the burden of this devastating disease. In this review article, the
most common oral precancerous lesions are discussed and the importance of early diagnosis is emphasized. In addition, the most
common non-invasive oral cancer devices that can aid the general practitioners in early diagnosis are also discussed.
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INTRODUCTION
The incidence of oral cancer worldwide is around 500 000 new cases
every year, accounting for approximately 3% of all malignancies, thus
creating a significant worldwide health problem.1 The American
Cancer Society estimated 40 250 new cases of these cancers for 2012
in the United States alone. Tobacco use and alcohol consumption are
regarded as the main risk factors for oral squamous cell carcinoma
(OSCC), while human papilloma virus (HPV) infection is emerging as
the leading risk factor in cancers of the oropharynx. The most com-
mon form of oral cancer is squamous cell carcinoma (SCC), which
accounts for 96% of all cancers of the oral cavity.2
The incidence of oral cancer has risen in the past decade and is
usually recognized when symptomatic and at a late stage. The overall
5-year survival rates for oral cancer have remained low at approxi-
mately 50% for the past decades and have remained among the worst
of all cancer death rates, considerably lower than that for colorectal,
cervix and breast origin. This is in part due to the lack of training of
health professionals for early detection and diagnosis. Despite signifi-
cant advances in cancer treatment, early detection of oral cancer and
its curable precursors remains the best way to ensure patient survival
and improved quality of life.3–4
Occurrence of oral cancer is most frequently after the age of 40
years, with a peak at 60 years of age. It also affects males twice as often
as females. The most common risk factors in this group are tobacco
and alcohol use. Recently, several studies suggest that head and neck
cancer particularly tongue cancer is increasing in young adults both
nationally and internationally.5 Factors that contribute to this rise are
still unknown, suspected etiologic agents include smokeless tobacco,
various forms of drug abuse, environmental factors and HPV (ref. 6).
The purpose of this review article is to summarize the most com-
mon oral precancerous conditions thatmay progress to oral cancer. In
addition, a review of the non-invasive detection techniques that are
currently being marketed to aid general dentists and other health-care
providers for early diagnosis of potential cancerous lesions is pre-
sented.
COMMON ORAL PRECANCEROUS LESIONS
It is well established that oral SCC occurs as a result of several molecular
and biochemical cellular alterations and changes in the underlying
fibrovascular stroma including neovascularization.7 In conjunction
with cellular alterations, clinical changes in the affected epithelial tissues
are observed as well, known as precancerous lesions. The clinical sig-
nificance of oral precancerous lesions lies in its association with malig-
nant transformation into OSCC (refs. 8–9). Oral precancerous lesions
can only be diagnosed histologically, although present as a spectrum of
epithelial changes, rather than distinct categories. The World Health
Organization in 2005 graded precancerous changes into mild, mo-
derate, severe and carcinoma in situ.10 The risk of malignant trans-
formation has been reported to be between 6.6% and 36.4%, although
a recent meta-analysis indicated a rate of 12.1%.11–12
The most common precancerous lesions present clinically as white,
red or a mix of white and red mucosal changes. These clinical condi-
tions are known as leukoplakia or erythroplakia. There are other
pathological conditions that are considered precancerous including
oral lichen planus and oral submucous fibrosis. In addition, less com-
mon lesions include discoid lupus erythematosus and some rare here-
ditary conditions such as dyskeraotisis congenita and epidermolysis
bullosa.3–4,6 The malignant potential of the above mentioned oral
lesions cannot be accurately predicted solely on the basis of their
clinical characteristics, histological evaluation is essential for all sus-
picious lesions. Unfortunately, histological findings only indicate that
a given lesionmay havemalignant potential (dysplasia), and cannot be
used for the prediction of malignant changes. Thus, the presence of
dysplasia only indicates that an oral lesion may have an increased risk
of malignant transformation. Molecular biomarkers capable of iden-
tifying the subset of lesions likely to progress to cancer are being widely
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investigated including genetic and epigenetic alterations observed in
oral mucosal precancerous lesions.13–19
ORAL LEUKOPLAKIA: A TARGET FOR EARLY ORAL CANCER
DETECTION
The earliest detectable morphologic changes of oral cancer are the
appearance of the ‘precancerous’ lesions, of which the most common
ones are leukoplakia and erythroplakia. Oral leukoplakia, a white
lesion in the mucosa of the oral cavity, represents the most common
precursor lesion of OSCC and its prevalence varies between 0.1% and
0.5%.3 Unfortunately, the reported proportion of oral leukoplakia
that develops into oral cancer varies depending on several factors
including, the study population, the definition of leukoplakia used
and the length of observation time, but an annual transformation rate
of 1%–2%per year is a reasonable assumption.13,20 Some of the known
risk factors for progression include, female gender, size of lesion and
the presence and grade of dysplasia.3–4 Although criteria have been
defined by the World Health Organization, it is difficult to make an
objective categorization of dysplasia owing to a high inter-observer
and intra-observer variation in assessment.10
Microscopically, leukoplakias exhibit either hyperplasia of kerati-
nocytes, which is characterized by hyperorthokeratosis, hyperparake-
ratosis, and acanthosis or several degrees of cellular atypia, which
classifies the lesion as either mild, moderate or severe dysplasia,
depending on the number of atypia present and extent of the involved
epithelium. The criteria for grading of oral epithelial dysplasia is uni-
versally well established and had been taught in most dental school’s
curriculum. If the epithelial cellular atypia invades the connective
tissue then the lesion is defined as an SCC (refs. 3–4, 10). For the oral
cavity, up to 20%–25% of biopsies obtained from clinically defined
leukoplakias may exhibit dysplasia; lesions located in the floor of the
mouth were reported up to 40% prevalence of dysplastic changes.9,11
Silverman and colleagues monitored 257 patients with oral leukopla-
kias, of which 22 had a diagnosis of epithelial dysplasia; eight of the 22
(36.4%) with dysplasia developed carcinoma. In their assessment, oral
leukoplakia had an association with the lifetime development of oral
cancer in affected individuals from 5% to 37% of the time. The time
from initial diagnosis of dysplasia to carcinoma ranged from 6months
to 39 years.21–22 Surgical excision is the standard treatment of local
lesions with epithelial dysplasia in the oral cavity; however, recurrence
rates have been reported as high as 50%.Whether recurrence relates to
continued exposure to risk factor such as smoking, or to an underlying
mechanism that initiates the original lesion remains unclear.13
Proliferative verrucous leukoplakia (PVL), considered to be either a
clinical subtype of non-homogeneous oral leukoplakia or to be a dis-
tinct clinical entity, is not strongly associated with smoking. It is cha-
racterized by multiple verrucous leukoplakic lesions and involves
various oral sites. These lesions may progress either to verrucous car-
cinoma or to SCC. In most cases, PVL is recognized only late in its
course since in its initial stages it is identical to an isolated leukoplakia.
Unfortunately, PVL lesions have a high tendency for recurrence after
excision.23
The problems with histological grading and treatment of the vari-
ous forms of leukoplakia have driven investigators to assess the risk for
progression and to identify targets for treatment. The presence and
number of cancer-associated genetic changes have proven to be effec-
tive in discriminating leukoplakias with a low risk from those with a
high risk of malignant transformation. In addition, to avoid painful
biopsies, saliva and exfoliated cells are now used as a source for bio-
marker-based risk assessment.14–16
ERYTHROPLAKIA
Although erythroplakia is an infrequent oral condition, its risk of
malignant progression is the highest among all oral precancerous
lesions. Erythroplakia is defined as ‘any lesion of the oral mucosa that
presents as bright red velvety plaques which cannot be characterized
clinically or pathologically as any other recognizable condition’. It can
appear anywhere in the oral cavity, but it predominately occurs in the
floor of the mouth, the soft palate, the ventral tongue and the tonsillar
fauces. These lesions are usually asymptomatic but sometimes patients
complain of a burning sensation and/or sore. Studies have shown that
malignant transformation ranges from 20% to 68%.24
Heavy alcohol consumption and tobacco use are known to be
important etiological factors of erythroplakia. The epithelium is often
atrophic and shows lack of keratin. Sometimes hyperplasia is seen as
well. The red color of erythroplakia is due to the epithelial thinness
that allows the underlying microvasculature to show through.
Erythroplakia needs to be treated because of its high risk of malignant
transformation. Surgery, either by cold knife or by laser excision, is the
recommended treatment modality. Unfortunately, there are very few
data from the literature about the recurrence rate after excision of
erythroplakias.20
HPV AND ORAL PRECANCEROUS LESIONS
HPVs are DNA viruses that can cause infection of either cutaneous or
mucosal epithelium depending on their genotype.25 The ones that
infect the mucosal epithelium has been categorized, depending on
their oncogenic potential, as either high-risk subtypes (HPV-16, 18,
31, 33 and 35), or low-risk subtypes (HPV-6, 11, 13 and 32). Low-risk
HPVs have been implicated in the pathogenesis of the benign oral
proliferative epithelial lesions, squamous cell papilloma, common
wart (verrucous vulgaris), condyloma acuminatum and focal epithe-
lial hyperplasia (Heck disease), while high-risk types, in particular
HPVs 16 and 18, have been associated with precancerous and cance-
rous oral and oropharyngeal epithelial lesions.26
The role of HPV in cervical cancer is well established and has led to
the widespread use of papillomavirus vaccines for young women. In
the contrary, the role of HPV in oral and oropharyngeal cancers is still
being investigated; although the reported prevalence varies consi-
derably, several studies have confirmed the presence of HPVs in oral
samples such as biopsies or brush samples of mucosa.27 In addition,
HPV positive normal oral mucosa have also been found in biopsies
from healthy mouths, but their prevalence is typically reported to be
higher in biopsies from oral lesions such as leukoplakia or cancers.
High-risk HPV genotypes, in particular HPV-16, are the most preva-
lent in oral leukoplakias, including PVL (ref. 25). The role of HPV in
the pathogenesis of oral leukoplakia and in its progression to carcin-
oma is unclear; there is a low viral load in HPV-cytopositive precan-
cerous and cancerous oral lesions, and viral integration is seldom
found. But the presence of HPV positive cells in orophayrhngeal car-
cinoma has been well documented.28–29
The course of malignant transformation in cells infected with onco-
genic HPV types is incompletely understood, but some components
are known.30 Virally encoded E6 binds simultaneously to the ubiqui-
tin/protein ligase E6AP and p53, resulting in ubiquitination of p53 and
its subsequent proteolytic degradation. Although the incidence of
tobacco- and alcohol-induced cancers is declining, there are solid
indications that the incidence as well as the prevalence of HPV-
associated head and neck squamous cell carcinomas is increasing.31
Future studies are needed to investigate the outcomes of HPV-
related oropharyngeal dysplastic lesions and evaluate potential
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screening methods to detect oropharyngeal dysplasia prior to cancer
progression. Successful screening measures used for cervical cancer
screening such as a Papanicolaou test, HPV polymerase chain reaction
testing, or both may be difficult to achieve, but there is meaningful
hope that prevention efforts will reduce the burden of HPV-related
oropharyngeal cancer.32
The available HPV vaccines have demonstrated significant ability to
prevent infection and dysplasia at anogenital sites; unfortunately, data
regarding oral HPV infection are lacking. Studies have to be initiated
to determine whether the prevalence of oral carcinomas declines along
with the expected decline in cervical cancer in women who receive the
HPV vaccines at a young age. However, it will take decades before any
potential benefit of HPV vaccination in reducing the rates of HPV-
related oropharyngeal carcinomas is confirmed.27
ORAL SUBMUCOUS FIBROSIS
Oral submucous fibrosis is a chronic, debilitating disease characteri-
zed by inflammation and progressive fibrosis of the submucosal tissues
(lamina propria and deeper connective tissues), resulting in marked
rigidity and an eventual inability to open the mouth. The buccal
mucosa is the most commonly involved site, but any part of the oral
cavity can be involved, even the pharynx. The condition is well recog-
nized for its malignant potential and is particularly associated with
areca nut chewing, the main component of betel quid.33 The mixture
of this quid or chew is a combination of the areca nut (fruit of the
Areca catechu palm tree, erroneously termed betel nut) and betel leaf
(from the Piper betel, a pepper shrub), tobacco, slaked lime (calcium
hydroxide) and catechu (extract of the Acacia catechu tree).34 The
pathogenesis of oral submucous fibrosis is not well established and
believed to be multifactorial. The cascade begins with a juxtaepithelial
inflammatory reaction in the oral mucosa, interspersed with healing
and fibrosis, with trismus being the end result.35
ORAL LICHEN PLANUS
Oral lichen planus (OLP) is a chronic inflammatory oral mucosal
disease of unknown etiology. OLP typically presents as white stria-
tions, white papules or white plaques. Other more symptomatic cli-
nical presentations include erythema, erosions, or blisters, which are
generally very painful. OLP affect predominantly the buccal mucosa,
tongue and gingiva, although other sites are occasionally involved.
OLP affects 1%–2% of the general adult population and is the most
common non-infectious oral mucosal disease. The potential malig-
nant transformation of OLP has been a lasting controversial matter.
Several retrospective studies have observed a higher incidence of oral
cancer in patients with a specific subtype of OLP, mainly erosive OLP
ranging from 2% to 8% which represents a greater risk of oral cancer
than in the general population. In this regard, OLP should be consi-
dered a potentially malignant condition.36
Even though the World Health Organization classified OLP as a
precancerous lesion,10 the premalignant or malignant potential of
OLP continues to be the subject of an ongoing and controversial
debate. Critics contend that the association between OLP and OSCC
is due to the misdiagnosis of dysplastic epithelial lesion as OLP, espe-
cially as it is often difficult to differentiate one from the other. A
recommendation was therefore made to differentiate carefully
between OLP lesions with dysplastic lesions.37–38
Lesions that are clinically indistinguishable from OLP but have a
distinct etiology are known as oral lichenoid lesions (OLLs), these
represent a common end point in response to extrinsic agents (drugs,
allergens), altered self-antigens or superantigens.39 These lesions share
common clinical and histopathological features with OLP and should
be considered oral precancerous conditions when they do not resolve
after the removal of the causative factor. Since OLLs are considered to
be precancerous, a recall system for patients with OLLmight be useful
to facilitate the early diagnosis of oral cancer with the aim of reducing
morbidity and mortality from oral cancer arising in OLL patients.39
The molecular mechanisms underlying OLP progression to OSCC
remains largely unknown. Further investigation of the genetic/protein
alterations in OLP and associated OSCC is warranted, which will lead
to a more complete understanding of the malignant potential of OLP
and help diagnose and treat OLP-associated OSCC patients at early
stage.40
IMPORTANCE OF EARLY DETECTION
There is general consensus that the clinical stage at the time of diag-
nosis is the most important predictor of recurrence and mortality in
oral cancer patients. The time to diagnosis is influenced by multiple
clinical and sociodemographic variables, including patient reluctance
to consult a health-care professional due to lack of access to health
care, especially in patients with low socioeconomic status, as well as
professional delay in diagnosing and treating the disease.40 Studies
have shown that dentists and other health-care providers are in des-
perate need of systemic educational updates in oral cancer prevention
and early detection, as they are remiss in the provision of oral exam-
inations and in the detection of early oral cancers. Clinicians can
improve patients’ survival rates if a cancerous lesion is detected at
an early stage, or if a precursor lesion (dysplasia) is discovered and
treated prior to malignant progression.41 A major challenge for early
diagnosis of the at-risk tissue is our limited ability to differentiate oral
precancerous lesions at high risk of progressing into invasive SCC
from those at low risk.42 Thus, the prevention of oral cancer and its
associatedmorbidity andmortality, hinges upon the early detection of
oral precancerous lesions, allowing for histological evaluation and
subsequent treatment depending on the stage of diagnosis. Early
detection and screening for oral cancer has the potential to decrease
themorbidity andmortality of disease, butmethods for screening have
not been proven successful. Although a typical routine oral cancer
examination requires a 90-s visual and tactile examination, too few
practitioners and dentists in particular are conducting these exams.43
NON-INVASIVE TOOLS FOR EARLY DETECTION
Recent advancements in oral cancer research have led to the develop-
ment of potentially useful diagnostic tools at the clinical andmolecular
level for the early detection of oral cancer. The gold standard for oral
cancer diagnosis remains tissue biopsy with histological assessment,
but this technique needs a trained health-care provider, and is con-
sidered invasive, painful, expensive and time consuming.43 Recent
clinical diagnostic tools for early detection of oral cancer include tolo-
nium chloride or toluidine blue dye, Oral CDx brush biopsy kits,
salivary diagnostics and lastly optical imaging systems. Depending
on the type of light and the imaging approaches used, optical imaging
of the oral tissues can detect minimal changes within the tissues, such
as alterations in tissue architecture and composition; expression of
specific biomarkers, vascularity/angiogenesis and perfusion; microa-
natomy and tissue boundary integrity (e.g., potential invasiveness of
lesions).44–45
The most common ones that have been marketed to dentists
include: ViziLite (Zila, Batesville, AR, USA), VELscope (LED Dental
Inc., Vancouver, Canada), DIFOTI (Electro-Optical Sciences, Inc.,
Irvington, NY, USA) and Identafi 3000 (DentalEZ, Bay Minette, AL,
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USA). All these methods have their own advantages and disadvantages
but unfortunately these non-invasive tools have failed in their prac-
tical implication in the community setup, as patients are still being
diagnosed in advanced stages of oral cancer.46–47
TOLUIDINE BLUE
Toluidine blue (TB) is a member of the thiazine group of metachro-
matic dyes, which binds to DNA and is partially soluble both in water
and in alcohol. Theoretically, dysplastic and malignant cells have higher
nucleic acid content than normal, and thus, staining of suspicious
lesions with this dye can aid recognition of mucosal changes. TB has
been used as a vital stain to highlight potentially malignant oral lesions
since the early 1980s. A positive staining of TB may appear as a dark
royal blue (Figure 1). TB test appears to be highly sensitive (97.8%–
93.5%) but less specific (92.9%–73.3%), mainly because of high false-
positive results.48–49 Recently, molecular studies on TB stained lesions
reported a link between carcinoma and loss of heterozygosity at 3p and
17p, while dysplasia resulted in loss of heterozygosity at 9p. The pre-
sence of loss of heterozygosity has also been reported in high frequency
of TB-stained lesions without or with low grade dysplasia.50
ORAL CDx
Oral CDx brush biopsy uses the concept of exfoliative cytology to
provide a cytological evaluation of a cellular dysplastic changes. The
oral CDx provides a complete transepithelial sample as the brush
extends deep in the epithelial layers. The oral cytological epithelial
samples are fixed onto a glass slide, stained with a modified
Papanicolaou test and analyzed microscopically via a computer-based
imaging system. However, although exfoliative cytology and brush
biopsy techniques are helpful in establishing a more definitive diag-
nosis of already visible lesions, they are of no value in detecting muco-
sal changes that are not readily visible to the naked eye.51–52 Advances
in the development of automated cytomorphometric methods com-
bined with genetic and proteomic profiling may provide the required
tools to refine screening strategies in the future.53–54 A scalpel biopsy is
still suggested if there is clinical suspicion of a lesion regardless of the
Oral CDx result.
CHEMILUMINESCENCE: VIZILITE
This imaging device has been approved for use in the United States by
the Food and Drug Administration since November 2001. It involves
the use of a hand-held, single-use, disposable chemiluminescent light
stick that emits light at 430, 540 and 580 nm wavelengths. The use of
the light stick is intended to improve the visual distinction between
normal mucosa and oral white lesions. Normal epithelium will absorb
light and appear dark whereas hyperkeratinized or dysplastic lesions
appear white. The difference in color could be related to altered epi-
thelial thickness, or to the higher density of nuclear content andmito-
chondrial matrix that preferentially reflect light in the pathological
tissues.55–56 Lately, a combination of both TB and ViziLite systems
(ViziLite Plus with TBlue System; Zila, Batesville, AR, USA), received
Food and Drug Administration clearance as an adjunct to visual exa-
mination of the oral cavity. A recent study of high risk patients showed
that themajority of lesions with a histological diagnosis of dysplasia or
carcinoma in situ were detected and mapped using ViziLite with TB
(ref. 57). Another new chemiluminescence device (MicroLuxDL; Zila,
Batesville, AR, USA) has been introduced as an adjunct tool for oral
lesion identification but few studies have been published to assess its
effectiveness in detecting precancerous lesions.58
VELSCOPE SYSTEM
The use of tissue autofluorescence in the screening and diagnosis of
precancerous lesions in the lung, uterine cervix and skin has been well
documented. This approach is already in clinical use in the lung, and
its mechanism of action and interaction of tissue autofluorescence has
been well described in the cervix.59–60
Using the tissue autofluorescence concept for diagnosis of dys-
plastic lesions in the oral cavity hinges on the changes in the structure
and metabolism of the epithelium and the subepithelial stroma when
interacting with light. Specifically, loss of autofluorescence in dys-
plastic and cancerous tissue is believed to reflect a complex mixture
of alterations to intrinsic tissue fluorophore distribution, due to tissue
remodeling such as the breakdown of the collagen matrix and elastin
composition as well as alterations to metabolism such as the decrease
in flavin adenine dinucleotide concentration, and increase the reduc-
tion form of nicotinamide adenine dinucleotide associated with pro-
gression of the disease.61–63 Further, these structural changes in tissue
morphology are associated with alterations not only in the epithelium
but also in the lamina propria (e.g., thickening of the epithelium,
hyperchromatin and increased cellular/nuclear pleomorphism, or
increased microvascularity). The latter changes lead to increased
absorption and/or scattering of light, which in turn reduces andmodi-
fies the detectable autofluorescence signal.64
In the past decade, several forms of autofluorescence technology
have been developed for inspection of the oral mucosa. In partnership
with the British Columbia Cancer Agency, LED Medical Diagnostics
Inc markets the hand-held VELscope System. It is a simple hand-held
fluorescence visualization tool for the direct visualization of tissue
Figure 1 TB stain on a suspicious lesion at the right lateral border of the tongue. (a) An erythroplakia lesion on right lateral border of the tongue of a 52-year-old
female. (b) Same lesion after application of the TB stain. TB was retained in some areas and not others. A biopsy was taken from the dark stained blue area which
showed a well differentiated squamous cell carcinoma lesion. TB, toluidine blue.
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fluorescence, and it is quick and easy to use. The site of interest is
viewed through the instrument eye piece. Normal oralmucosa appears
pale green due to the tissue autofluorescence resulting from stimulation
with intense blue light excitation at 400–460 nm wavelength. In con-
trast, dysplastic and malignant lesions will appear darker than the sur-
rounding healthy tissues as they have decreased autofluorescence.65–67
Two recent studies emphasized the controversial use of this system
for early diagnosis. One study, demonstrated that VELscope examina-
tion did not provide a definitive diagnosis regarding the presence of
epithelial dysplasia, and that loss of autofluorescence is not useful in
diagnosing epithelial dysplasia without relevant clinical interpreta-
tion.68 While the other study showed that the VELscope was useful
in confirming the presence of oral leukoplakia and erythroplakia and
other oral mucosal disorders, but the device was unable to discri-
minate high-risk from low-risk lesions.69
IDENTAFI 3000
The Identafi 3000 technology combines anatomical imaging with
fluorescence, fiber optics and confocal microscopy to map and deli-
neate precisely the lesion in the area being screened. The advantage of
this device over the Velscope is its small size and easy accessibility to all
tissues in the oral cavity.70 Besides detection of autoflurescence similar
to the Velscope system (Figure 2b), this device also examines tissue
reflectance which is based on the premise of detecting changes in
angiogenesis with green-amber light (540- to 575-nm wavelength)
illumination (Figure 2c). The amber light is thought to enhance the
reflective properties of the oralmucosa, allowing a distinction between
normal and abnormal tissue vasculature. Increased angiogenesis is a
known process during oral carcinogenesis and oral cancer progres-
sion.71–72 It is important to develop imaging technology for evaluating
the status of tumor angiogenesis.
A recent study using the Identafi 3000 for screening of 124 subjects,
demonstrated a sensitivity of 82% and a specificity of 87% in diffe-
rentiating between neoplastic and non-neoplastic oral conditions.
Results appeared to vary between sampling depths, and keratinized
vs. non-keratinized tissues.73 Another study using quantitative fluo-
rescence imaging in 56 patients with oral lesions and 11 normal volun-
teers, showed that healthy tissue could be discriminated from dyspla-
sia and invasive cancer with 95.9% sensitivity and 96.2% specificity in
the training set, and with 100% sensitivity and 91.4% specificity in the
validation set.74 Further clinical studies are needed in diverse popula-
tions to evaluate fully the clinical usefulness of this promising tech-
nology.75
SALIVA AS A DIAGNOSTIC TOOL
Saliva from patients has been used in a novel way to provide molecular
biomarkers for oral cancer detection. Saliva is a mirror of the body,
reflecting virtually the entire spectrum of normal and disease states
and its use as a diagnostic fluid meets the demands for an inexpensive,
non-invasive and accessible diagnostic tool. Discovery of analytes in
saliva of normal and diseased subjects suggests a very promising function
of saliva as a local and systematic diagnostic tool.76–77 The ability to
analyze saliva to monitor health and disease is a highly desirable goal
for oral health promotion and research. So far, saliva has been used to
detect caries risk, periodontitis, oral cancer, breast cancer, salivary gland
diseases and systemic disorders such as human immunodefficiency virus
and hepatitis C virus.78 However, due to lack of knowledge of disease
markers and an overall low concentration of these markers in saliva
when compared to serum, the diagnostic value of saliva has not been
fully realized. However, nowadays, highly sensitive and high-throughput
assays such as DNA microarray, mass spectrometry and nanoscale sen-
sors can measure protein and RNA markers at low concentrations in
saliva, thus expanding the utility of saliva as a diagnostic tool.79–80
CONCLUSION AND FUTURE DIRECTIONS
Dentists’ knowledge and education in detecting oral cancer at its pre-
cancerous phase is the key to prevent its progression to later stages. In
order to improve early detection, it is imperative to increase the
health-care providers’ depth of knowledge about oral cancer, their risk
factors and the most common oral precancerous conditions. Future
research can also be directed towards establishing appropriate clinical
practice standards for early detection exams. Currently, the new
innovative visual-based techniques show promising results, but lack
strong evidence to support their effectiveness in early detection. Their
utilization in clinic practice is still anecdotal. Limitations that hinder
their wide use include lack of methodologically sound clinical trials,
their correlation with histological alterations and the impact these
techniques have on a patient’s survival and risk of disease recurrence.
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